Andreev K, Jones JC, Seiler P, Kandeil A, Turner J. Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023. J Infect Dis. 2023 Sep 28:jiad418
The antiviral susceptibility of currently circulating (2022-2023) highly pathogenic avian influenza (HPAI) A(H5N1) viruses was assessed by genotypic and phenotypic approaches. The frequency of neuraminidase (NA) and polymerase acidic (PA) substitutions associated with reduced inhibition by NA inhibitors (NAIs) (21/2698, 0.78%) or by the PA inhibitor baloxavir (14/2600, 0.54%) was low. Phenotypic testing of 22 clade 2.3.2.1a and 2.3.4.4b viruses revealed broad susceptibility to NAIs and baloxavir concluding that most contemporary HPAI A(H5N1) viruses retain susceptibility to antiviral drugs. Novel NA-K432E and NA-T438I substitutions (N2 numbering) were identified at elevated frequencies (104/2698, 3.85%) and caused reduced zanamivir and peramivir inhibition.
See Also:
Latest articles in those days:
- Purine nucleoside phosphorylase dominates Influenza A virus replication and host hyperinflammation through purine salvage 15 hours ago
- Pathogenicity and transmissibility of bovine-derived HPAI H5N1 B3.13 virus in pigs 15 hours ago
- Genetic Characterization of Influenza A Viruses Circulating in Hong Kong, China, 2023: The first influenza epidemic after the lifting of 2.5 years of COVID-19 non-pharmaceutical interventions 15 hours ago
- Assessment of the public health risk of novel reassortant H3N3 avian influenza viruses that emerged in chickens 15 hours ago
- Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 2 days ago
[Go Top] [Close Window]
